Primary Thromboprophylaxis with Heparins for Arteriovenous Fistula Failure in Pediatric Patients

Abstract

Background

To reduce the incidence of early arteriovenous fistula failure (AVF) due to thrombosis in pediatric hemodialysis (HD) patients, a primary thromboprophylaxis (PTP) protocol was initiated at author's institution in June 2005. The goal of this study is to report author's experience with this protocol one year later.

Methods and Results

19 AVFs (14 patients, Historical group) and 8 AVFs (7 patients, PTP group) were created prior to and after initiation of PTP respectively. PTP consisted of unfractionated heparin (5–10 units/kg/hr) infusion postoperatively, followed by subcutaneous low molecular weigh heparin (LMWH) until AVF was matured. LMWH dosing was “Prophylactic” (0.5 mg/kg/d, anti-factor Xa levels: peak 0.25–0.5 and trough < 0.3 units/mL) and “Therapeutic” (1 mg/kg/d, anti-factor Xa level: peak 0.5-1 and trough < 0.5 units/mL) based on thrombosis predisposition. In Historical group, 12 AVFs did not receive thromboprophylaxis (No-treatment group), 5 received 81 mg aspirin/day (Aspirin group), and 2 received LMWH. In No-treatment group 10/12 AVFs failed: 9 thromboses and 1 stenosis. In Aspirin group 1/5 AVFs failed due to thrombosis. In PTP group 1/8 AVFs failed due to stenosis; the first 2 AVFs developed hematoma prompting a reduction in LMWH dose and monitoring trough anti-factor Xa levels, one AVF required thrombectomy after LMWH was transiently held. The incidence of thrombosis was less in PTP group (12.5%) when comparing to No-treatment group (83%) (p < 0.05).

Conclusion

PTP is a feasible option to prevent early thrombosis at AVF. Close clinical and laboratory monitoring including trough anti-factor Xa levels is required to adjust optimum anticoagulation. Larger studies are needed to clarify safety and efficacy of our PTP protocol.

Keywords

Hemodialysis Arteriovenous fistula (AVF)Low molecular weight heparin (LMWH)Child

Get full access to this article

View all access options for this article.

References

III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000. Am J Kidney Dis 2001; 37: S137–S181.

Ethier

J.H.

, Lindsay

R.M.

, Barre

P.E.

, Kappel

J.E.

, Carlisle

E.J.

, Common

Clinical practice guidelines for vascular access. Canadian Society of Nephrology.

J Am Soc Nephrol 1999; 10(Suppl 13): S297–S305.

Dhingra

R.K.

, Young

E.W.

, Hulbert-Shearon

T.E.

, Leavey

S.F.

, Port

F.K.

Type of vascular access and mortality in U.S. hemodialysis patients.

Kidney Int 2001; 60: 1443–51.

Lee

, Manns

, Taub

Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access.

Am J Kidney Dis 2002; 40: 611–22.

Rayner

H.C.

, Besarab

, Brown

W.W.

, Disney

, Saito

, Pisoni

R.L.

Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines.

Am J Kidney Dis 2004; 44: 22–6.

Rayner

H.C.

, Pisoni

R.L.

, Bommer

Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Nephrol Dial Transplant 2004; 19: 108–20.

Chand

D.H.

, Brier

, Strife

C.F.

Comparison of vascular access type in pediatric hemodialysis patients with respect to urea clearance, anemia management, and serum albumin concentration.

Am J Kidney Dis 2005; 45: 303–8.

Feldman

H.I.

, Held

P.J.

, Hutchinson

J.T.

Hemodialysis vascular access morbidity in the United States.

Kidney Int 1993; 43: 1091–6.

Hakim

, Himmelfarb

Hemodialysis access failure: a call to action.

Kidney Int 1998; 54: 1029–40.

10.

Patel

N.H.

, Revanur

V.K.

, Khanna

Vascular access for hemodialysis: an indepth review.

J Nephrol 2001; 14: 532.

11.

Robbin

M.L.

, Chamberlain

N.E.

, Lockhart

M.E.

Hemodialysis arteriovenous fistula maturity: US evaluation.

Radiology 2002; 225: 59–64.

12.

Bourquelot

, Gagnadoux

M.F.

Vascular access for hemodialysis in children.

Pediatr Nephrol 1997; 11: 659–60.

13.

Kreidy

, Ghabril

Arteriovenous fistula for chronic hemodialysis in children.

J Med Liban 2000; 48: 288–93.

14.

Lumsden

A.B.

, MacDonald

M.J.

, Allen

R.C.

, Dodson

T.F.

Hemodialysis access in the pediatric patient population.

Am J Surg 1994; 168: 197–201.

15.

Ramage

I.J.

, Bailie

, Tyerman

K.S.

, McColl

J.H.

, Pollard

S.G.

, Fitzpatrick

M.M.

Vascular access survival in children and young adults receiving long-term hemodialysis.

Am J Kidney Dis 2005; 45: 708–14.

16.

Sheth

R.D.

, Brandt

M.L.

, Brewer

E.D.

, Nuchtern

J.G.

, Kale

A.S.

, Goldstein

S.L.

Permanent hemodialysis vascular access survival in children and adolescents with end-stage renal disease.

Kidney Int 2002; 62: 1864–9.

17.

Sanabia

, Polo

J.R.

, Morales

M.D.

, Canals

M.J.

, Polo

, Serantes

Microsurgery in gaining paediatric vascular access for haemodialysis.

Microsurgery 1993; 14: 276–9.

18.

Erdem

, Haznedaroglu

I.C.

, Celik

Coagulation, fibrinolysis and fibrinolysis inhibitors in haemodialysis patients: contribution of arteriovenous fistula.

Nephrol Dial Transplant 1996; 11: 1299–305.

19.

Kowalewski

, Zimnoch

, Wojtukiewicz

M.Z.

Coagulation activators and inhibitors in the neointima of polyester vascular grafts.

Blood Coagul Fibrinolysis 2003; 14: 433–9.

20.

Mackman

Role of tissue factor in hemostasis, thrombosis, and vascular development.

Arterioscler Thromb Vasc Biol 2004; 24: 1015–22.

21.

Chen

, Lopez

J.A.

Interactions of platelets with subendothelium and endothelium.

Microcirculation 2005; 12: 235–46.

22.

Dunkley

, Harrison

Platelet activation can occur by shear stress alone in the PFA-100 platelet analyser.

Platelets 2005; 16: 81–4.

23.

Fiskerstrand

C.E.

, Burne

M.E.

, Willim

Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis.

Artif Organs 1985; 9: 61–3.

24.

Grontoft

K.C.

, Mulec

, Gutierrez

, Olander

Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis.

Scand J Urol Nephrol 1985; 19: 55–7.

25.

Harter

H.R.

, Burch

J.W.

, Majerus

P.W.

Prevention of thrombosis in patients on hemodialysis by low-dose aspirin.

N Engl J Med 1979; 301: 577–9.

26.

Janicki

, Dmoszynska

, Janicka

Influence of antiplatelet drugs on occlusion of arteriovenous fistula in uraemic patients.

Int Urol Nephrol 1992; 24: 83–9.

27.

Grontoft

K.C.

, Larsson

, Mulec

, Weiss

L.G.

, Dickinson

J.P.

Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group.

Scand J Urol Nephrol 1998; 32: 276–83.

28.

Kaufman

J.S.

, O'Connor

T.Z.

, Zhang

J.H.Y.

Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis.

J Am Soc Nephrol 2003; 14: 2313–21.

29.

Sreedhara

, Himmelfarb

, Lazarus

J.M.

, Hakim

R.M.

Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study.

Kidney Int 1994; 45: 1477–83.

30.

Harvey

, Bredenberg

C.E.

, Couper

, Himmelfarb

Aspirin enhances platelet-derived growth factor-induced vascular smooth muscle cell proliferation.

J Vasc Surg 1997; 25: 689–95.

31.

Freeman

R.V.

, Mehta

R.H.

, Al

B.W.

, Cooper

J.V.

, Kline-Rogers

, Eagle

K.A.

Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors.

J Am Coll Cardiol 2003; 41: 718–24.

32.

Yevzlin

A.S.

, Conley

E.L.

, Sanchez

R.J.

, Young

H.N.

, Becker

B.N.

Vascular access outcomes and medication use: a USRDS study.

Semin Dial 2006; 19: 535–9.

33.

Crowther

M.A.

, Clase

C.M.

, Margetts

P.J.

Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial.

J Am Soc Nephrol 2002; 13: 2331–7.

34.

Lopez-Sanchez

, Gonzalez-Fernandez

, Valero-Diaz de

L.C.

, Dominguez-Artiga

M.J.

, Hernandez-Hernandez

M.A.

Enoxaparin, retroperitoneal haematoma in the elderly and impaired renal function.

Anaesth Intensive Care 2005; 33: 689–90.

35.

Malik

, Capling

, Bastani

Enoxaparin-associated retroperitoneal bleeding in two patients with renal insufficiency.

Pharmacotherapy 2005; 25: 769–72.

36.

Remuzzi

Bleeding in renal failure.

Lancet 1988; 1: 1205–8.

37.

Da Silva

M.S.

, Sobel

Anticoagulants: to bleed or not to bleed, that is the question.

SeminVasc Surg 2002; 15: 256–67.

38.

Sobel

, McNeill

P.M.

, Carlson

P.L.

Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo.

J Clin Invest 1991; 87: 1787–93.

39.

Bowles

, Cohen

Inherited thrombophilias and anticoagulation in pregnancy.

Best Pract Res Clin Obstet Gynaecol 2003; 17: 471–89.

40.

Haas

, Wolf

, Kakkar

A.K.

Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin.

Thromb Haemost 2005; 94: 814–9.

41.

Hamad

G.G.

, Choban

P.S.

Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study.

Obes Surg 2005; 15: 1368–74.

42.

Hull

R.D.

, Schellong

S.M.

, Tapson

V.F.

Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study.

J Thromb Thrombolysis 2006; 22: 31–8.

43.

Rasmussen

M.S.

, Jorgensen

L.N.

, Wille-Jorgensen

Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study.

J Thromb Haemost 2006; 4: 2384–90.

44.

Deruelle

, Denervaud

, Hachulla

Use of low-molecular-weight heparin from the first trimester of pregnancy: A retrospective study of 111 consecutive pregnancies.

Eur J Obstet Gynecol Reprod Biol 2006; 127: 73–8.

45.

Dix

, Andrew

, Marzinotto

The use of low molecular weight heparin in pediatric patients: a prospective cohort study.

J Pediatr 2000; 136: 439–45.

46.

Monagle

, Chan

, Massicotte

, Chalmers

, Michelson

A.D.

Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Chest 2004; 126: 645S–87S.

47.

Kranz

, Vester

, Nadalin

, Paul

, Broelsch

C.E.

, Hoyer

P.F.

Outcome after kidney transplantation in children with thrombotic risk factors.

Pediatr Transplant 2006; 10: 788–93.

48.

Gaspari

, Vigano

, Orisio

, Bonati

, Livio

, Remuzzi

Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition.

J Clin Invest 1987; 79: 1788–97.

49.

Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.

50.

Barba

, Marco

, Martin-Alvarez

The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE).

J Thromb Haemost 2005; 3: 856–62.

51.

Nagge

, Crowther

, Hirsh

Is impaired renal function a contraindication to the use of low-molecular-weight heparin?

Arch Intern Med 2002; 162: 2605–9.

52.

Perry

S.L.

, O'Shea

S.I.

, Byrne

, Szczech

L.A.

, Ortel

T.L.

A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients.

Thromb Haemost 2006; 96: 750–5.

53.

Stobe

, Siegemund

, Achenbach

, Preiss

Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency.

Int J Clin Pharmacol Ther 2006; 44: 455–65.

54.

Lim

, Dentali

, Eikelboom

J.W.

, Crowther

M.A.

Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.

Ann Intern Med 2006; 144: 673–84.

55.

Sharathkumar

, Revel-Vilk

, Chan

A.K.

, Marzi-notto

, Andrew

, Massicotte

M.P.

Outcome of children with thromboembolic events (TEs) treated with low molecular weight heparin (LMWH).

J Pediatr Hematol Oncol 2003; 24: A1.

56.

Overholser

B.R.

, Brophy

D.F.

, Sowinski

K.M.

Development of an efficient sampling strategy to predict enoxaparin pharmacokinetics in stage 5 chronic kidney disease.

Ther Drug Monit 2006; 28: 807–12.